ARQT

Arcutis reported its Q1 2026 financial results on May 6, 2026, with net product revenues of $105.4 million, a 65% increase compared to Q1 2025, but a 17% sequential decline from Q4 2025. The company maintained its full-year 2026 revenue guidance of $480 million to $495 million. Arcutis submitted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the FDA to expand its indication for atopic dermatitis to infants aged 3 to 24 months. A PDUFA action for pediatric psoriasis (ZORYVE cream 0.3%) is anticipated on June 29, 2026. The stock price of ARQT has decreased by 27.1% since the beginning of 2026.